Proprietary Streptamer™ reversible reagents for cell therapy manufacturing
A fully automated process enabling a high recovery of T cells
Selective expansion and activation while decreasing processing time and costs
10.30 Creating a Universal Donor based Cell Therapy
Director. Immuno-Oncology External Research & Innovation, Servier
How to make off-the-shelf, industrialized CAR-TCR therapies?
Safety of Allogeneic therapies
Durability of allogeneic CAR-Ts
Requirements of Allogeneic products
Developing allogeneic or universal donor cell therapies
Current progress in allogenic space
11.00 Morning Refreshments & Networking
Improving Cell and Process Quality for Flawless Transactions
11.30 BD Solutions in Cell Therapy Development and Production
Scientific Affairs Director Europe , BD Biosciences
In depth-characterization of cell preparation is central to the optimization of cell production and the development of successful cell therapies. Fluorescent Activated cell sorting (FACS) delivers a unique solution, providing high-content information at the
single cell level.
The BD FACSLyric™ cell analyzer enables standardization and consistency across instruments, time, operators and sites making it an ideal platform for the evaluation of cell preparations and release test development.
BD FACS™ cytometer systems can be matched with custom, dried reagent panels and automated analysis for further improvements in consistency and standardization.
Achieving a high yield of one specific cell population is a key step toward successfully developing cell therapies. A currently in development BD sorter aims to provide an approach to achieving high purity and protected sterility for your cell populations.
12.00 Development of TCR-engineered T Cell Therapies for solid tumors: From Target to T Cell Product
Immatics has a proprietary tumor antigen targets discovery platform, XPRESIDENT® The platform not only identifies novel tumor-specific targets, but also screens TCR candidates against off-target toxicities in absence of reliable in vivo models
Selected TCRs against these specific peptide targets are used in Immatics’ TCR-based ACTengine® programs (Adoptive Cellular Therapy with autologous engineered T cells)
Extensive process development was carried out using primary T cells derived from multiple healthy donors to optimize each step in the manufacturing of IMA201 and IMA202 products and confirmed using T cells from cancer patients
Process Qualification runs were successfully completed in GMP environment for both engineered TCR T-cell products in anticipation for patient enrolment in 2 clinical trials IMA201-101 and IMA202-101
12.30 Lunch & Networking
Ensuring Cost Effective Scalability: Up & Out
13.30 Automated Manufacturing of Clinical-Scale Gene-Engineered T Cells Using the CliniMACS Prodigy
Manufacturing gene-engineered T cells like chimeric antigen receptor (CAR) T cells is both time consuming and labor intensive. The CliniMACS Prodigy is a device for the automated production of CAR T cells
Manufacturing occurs in a single-use closed tubing set that protects the user and sample from contamination
Our CliniMACS Reagents have been developed ready to be easily used with the CliniMACS Prodigy
Using the CliniMACS Prodigy, we can expand CAR T cells ready for adoptive cell therapy. The future is here
DoubleTree by Hilton Hotel London – Docklands Riverside
265 Rotherhithe Street,
Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.